RBN-2397 has the potential to become a new anticancer drug that could not only directly suppress tumor growth but also enhance the immune response to cancer cells by inhibiting PARP7, a molecule which plays a key role in cancer survival.
Under the terms of the agreement, ONO will have exclusive rights to develop and commercialize RBN-2397 in
We are pleased to be collaborating with Ribon, a pioneer in the development of novel precision oncology drugs targeting stress support pathways', said
This agreement enables us to strategically expand our program in support of Ribon's mission to bring therapeutics targeting stress support pathways for the treatment of cancer to as many appropriate patients as possible,' said
About RBN-2397
RBN-2397, is an orally available small molecule inhibitor of PARP7 that Ribon is developing for the treatment of solid tumors. PARP7 is upregulated in response to cellular stress, including genomic instability in cancers, and acts as a brake on the cellular stress response by negatively regulating the Type I interferon response. By inhibiting PARP7 in tumor cells, RBN-2397 has been shown to directly inhibit cellular proliferation and restore interferon signaling to stimulate an innate and adaptive antitumor immune response. RBN-2397 is currently in a Phase 1 dose-escalation clinical trial as a monotherapy in patients with advanced solid tumors to primarily assess safety and tolerability. PARP7 is overexpressed in a number of tumors, including squamous cell carcinoma of the lung, or
About
Ribon Therapeutics is a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. Ribon is exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. Leveraging its proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform, Ribon is building a pipeline of selective, small molecule inhibitors to numerous NAD+-utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas. Ribon's lead program is RBN-2397, a first-in-class PARP7 inhibitor in clinical development for the treatment of cancer. Ribon is located in
Contact:
Email: publicrelations@ono.co.jp
(C) 2021 Electronic News Publishing, source